Efficacy of NAC for intervertebral disc degeneration.

Phase 2

Active, not recruiting

• Conditions: Patients judged by heavy doctors to be difficult to continue; Lumbar disc degeneration, Disc herniation

• Registration Number: JPRN-jRCTs031180436
• Lead Sponsor: Watanabe Kota

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-03-27
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1) Patients with lumbar disc degeneration based on images(Pfirrmann grade: 3, 4) and neurological findings
2) Age From 20 years old to less than 65 years old
3) During the study period, anti-inflammatory / analgesic agents (NSAIDs including COX-2 inhibitors, an extract from Inflamed cutaneous tissue of rabbits inoculated with Vaccinia Virus (neurotropin), antioxidant vitamin E formulation(yubera), as well as steroidal agents (oral preparation and injection)), those who agree to discontinue the use.

Exclusion Criteria

1) Patients with complications such as severe heart, lung, liver, and blood diseases
2) Patients who received surgical treatment judged by the attending physician to affect the exam
3) Patients whose ALT / AST values before administration exceed 3 times the institution standard value
4) Currently, supplements containing NAC or NAC or supplements with antioxidant action (vitamin E) ingested
5) Patients who are allergic to drugs including NAC
6) Women who are pregnant, nursing, maybe pregnant or prefer pregnant during treatment
7) Patients who have undergone spinal surgery in the past
8) Others, patients who are judged to be unacceptable as subjects of this study by the investigator or shared medical doctor

Study & Design

• Study Type: Interventional
• Study Design: Not specified